Last updated:
CRISPR applications in brewing are both more advanced and more nuanced than the general science media coverage suggests. I’ve followed this area closely because the distinction between what CRISPR has actually delivered in brewing yeast engineering versus what’s been proposed or is in development matters for understanding current commercial brewing strains and anticipating where the technology is heading. CRISPR-Cas9 is genuinely effective for precision yeast engineering, it enables targeted genetic modifications that would take years to achieve through conventional breeding, if they were achievable at all. But most commercially available brewing yeast developments marketed as CRISPR-derived are more accurately described as CRISPR-assisted conventional breeding.
What CRISPR actually enables in yeast engineering
CRISPR-Cas9 is a gene editing system that allows precise targeting and modification of specific DNA sequences. In brewing yeast applications, the primary uses are: Gene knockouts: Disabling genes that produce undesirable fermentation byproducts. The most commercially significant example is disabling the FLO8 gene pathway to eliminate diastaticus (superattenuation) potential from Saccharomyces cerevisiae strains, diastaticus yeast can ferment dextrins that normal brewing yeast can’t, causing refermentation in packaged beers. CRISPR-based FLO8 knockouts are cleaner and more stable than conventional screening methods. Gene upregulation: Increasing expression of genes like IRC7 (for thiol release) by modifying promoter sequences to drive higher enzyme production, producing the “thiolized” yeast effect more precisely than directed evolution approaches. Heterologous gene insertion: Inserting genes from other organisms, the ALDC (alpha-acetolactate decarboxylase) gene from bacteria, for example, is inserted into some commercial brewing yeast strains to bypass the diacetyl formation pathway and eliminate the need for diacetyl rest. Targeted breeding assistance: Using CRISPR to create specific genetic markers or modifications that enable faster conventional strain development through marker-assisted selection.
Regulatory status of CRISPR-modified brewing yeast
The regulatory treatment of CRISPR-modified yeast used in brewing varies significantly by jurisdiction. In the US, the FDA has generally treated gene-edited organisms (including CRISPR-modified yeast) used as processing aids (not present in the final product in viable form) without the same stringent review required for GMO food ingredients, particularly for edits that could theoretically have been produced by conventional mutagenesis. In the EU, the European Court of Justice’s 2018 ruling treating gene-edited organisms under the same framework as conventional GMOs created stricter regulatory requirements for commercial use. For homebrewers, the CRISPR-developed commercial yeast strains available from White Labs, Lallemand, and Omega Yeast are legal to purchase and use, the regulatory complexity affects commercial brewing and food production applications, not homebrew supply.
Common Questions
Will CRISPR make brewing yeast with entirely new flavor capabilities?
CRISPR and related gene editing tools will expand the flavor capability of brewing yeast beyond what’s achievable through conventional breeding, but the timeline and extent of that expansion depends on which specific capabilities are being targeted. Near-term (already being done or in advanced development): enhanced thiol release from existing precursors, diastaticus-free versions of currently popular strains, reduced diacetyl production, and cold-active fermentation capability in S. cerevisiae backgrounds. Medium-term (research-stage): yeast strains that produce novel terpenes not naturally present in S. cerevisiae, strains engineered to produce specific fruity ester combinations by tuning the enzyme pathways governing ester synthesis, and strains with modified cell wall properties for improved flocculation control. Long-term speculation: yeast strains that substantially biosynthesize hop-like aromatic compounds from simpler carbon sources, potentially reducing hop dependence in certain beer styles. The constraint isn’t gene editing capability, CRISPR can make these modifications technically, it’s the regulatory pathway, commercial development investment, and consumer acceptance of GMO-derived ingredients in beer that will pace the timeline from research to commercial availability.
